Pfizer (PFE) R&D president has 816 shares withheld for taxes on RSU vesting
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Pfizer Inc. President, R&D Christoffel Boshoff had 816 shares of common stock withheld on February 23, 2026 to cover tax obligations upon the vesting of restricted stock units, at a price of $27.06 per share. After this tax-withholding disposition, he directly holds 154,829 shares and indirectly holds 709 shares through a Rule 16b-3 plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
BOSHOFF CHRISTOFFEL
Role
President, R&D
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 816 | $27.06 | $22K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 154,829 shares (Direct);
Common Stock — 709 shares (Indirect, By Rule 16b-3 Plan)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did Pfizer (PFE) report for Christoffel Boshoff?
Pfizer reported a tax-related share withholding for Christoffel Boshoff. 816 common shares were withheld to satisfy tax obligations when restricted stock units vested, rather than an open-market sale, at a price of $27.06 per share on February 23, 2026.
Is the Pfizer (PFE) Form 4 for Christoffel Boshoff an open-market sale?
No, the Form 4 reflects a tax-withholding disposition, not an open-market sale. Shares were withheld to satisfy tax obligations when restricted stock units vested, which is categorized under transaction code F, rather than a voluntary market transaction.
What does transaction code F mean in the Pfizer (PFE) Form 4 filing?
Transaction code F indicates a tax-withholding disposition in this context. It reflects payment of tax liability by delivering or withholding securities upon vesting of restricted stock units, rather than a standard buy or sell in the open market.
What role does Christoffel Boshoff hold at Pfizer (PFE) in this Form 4?
Christoffel Boshoff is identified as an officer of Pfizer, serving as President, R&D. This role is disclosed in the Form 4 reporting his tax-related share withholding tied to the vesting of restricted stock units.